Onset of efficacy of tolterodine extended release in patients with overactive bladder

By Sussman David O.   Kraus Stephen R.   Carlsson Martin   Guan Zhonghong  

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 777-781

Informa Healthcare

Access to resources Recommend Favorite

Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study

By Herschorn S.   Pommerville P.   Stothers L.   Egerdie B.   Gajewski J.   Carlson K.   Radomski S.   Drutz H.   Schulz J.   Barkin J.   Hirshberg E.   Corcos J.  

Current Medical Research and Opinion, Vol. 27, Iss. 2, 2011-02 ,pp. : 375-382

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom

By Hart Warren Mark   Abrams Paul   Munro Vicki   Retsa Peny   Nazir Jameel  

Journal of Medical Economics, Vol. 16, Iss. 10, 2013-10 ,pp. : 1246-1254

Informa Healthcare

Access to resources Recommend Favorite

Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder

By Bolge Susan C.   McDonnell Diana D.   Chen Andrew   Wan George J.  

Current Medical Research and Opinion, Vol. 23, Iss. 8, 2007-08 ,pp. : 1903-1912

Informa Healthcare

Access to resources Recommend Favorite

The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double‐blind, placebo‐controlled phase 2 study

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 2, 2015-02 ,pp. : 242-250

John Wiley & Sons Inc

Access to resources Recommend Favorite